Blog & Resources Camargo Blog November 5th, 2007

Foreign Inspections by FDA

The US General Accounting Office (GAO) criticised what it concluded is a lack of FDA inspection of foreign API and finished dosage form manufacturers. This has received a lot of coverage in the lay and professional press, especially since a huge increase in API’s is coming from China; FDA has only 13 inspections scheduled in China, a country with over 700 drug manufacturers.

Camargo’s experience with sourcing API’s in China has not been good. Due to quality concerns we greatly expanded the scope of testing attributes. We found benzene (a carcinogen) in startling amounts in one API lot. After investigation, we learned that the Chinese drug manufacturer had recently been a paint manufacturer and had cleaned all the vessels and pipe with benzene.

However, our efforts show that US manufacturers don’t rely on the FDA to assure safety of pharmaceuticals. As Bruce Downey, CEO of Barr Laboratories and head of the Generic Pharmaceutical Association, testified at a congressional hearing, that US drug firms inspect suppliers and perform extensive product testing.

Moreover, FDA does extensive checking before product approval and reviews all changes in sources through the DMF (Drug Mater File) system. The DMF is a record of the manufacturing process, quality and stability of every ingredient and packaging material.

Reference: The current FDA Guide to Foreign Inspections

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.

Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.

9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights